What is the Association of Aspirin Use with Cardiovascular Events and Bleeding Events in Individuals Without Cardiovascular Disease?

This new analysis was done to bring together the total evidence on aspirin in primary prevention of cardiovascular disease now available in a mixed population

• Sean Zheng is the lead author of the new meta-analysis
• "A review of the evidence for use of aspirin in primary prevention was last looked at 5 or 6 years ago but now we have additional data from three new trials published last year — ARRIVE in people at higher CV risk, ASCEND in people with diabetes, and ASPREE in older individuals"
• "This new analysis was done to bring together the total evidence on aspirin in primary prevention of cardiovascular disease now available in a mixed population"
• "We found that aspirin did reduce cardiovascular events by a modest 11%, with a number needed to treat to prevent one event of 265, but it also increased major bleeding, such as serious GI bleed, intracranial bleed or bleed needing hospitalization or transfusion by 43%. That is a number needed to harm of 210"

Read More:

jamanetwork.com/journals/jama/article-abstract/2721178

www.medscape.com/viewarticle/908161?src=wnl_tp10n_190214_mscpedit&uac=151849FY&impID=1879637&faf=1